Trial Profile
An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms AvaALL
- Sponsors Roche
- 02 Jun 2017 Primary endpoint notmet. (overall survival) as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Results (Data cut-off: 24 Jun 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 15 Sep 2016 Status changed from active, no longer recruiting to completed.